AU783899B2 - Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same - Google Patents

Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same Download PDF

Info

Publication number
AU783899B2
AU783899B2 AU26677/01A AU2667701A AU783899B2 AU 783899 B2 AU783899 B2 AU 783899B2 AU 26677/01 A AU26677/01 A AU 26677/01A AU 2667701 A AU2667701 A AU 2667701A AU 783899 B2 AU783899 B2 AU 783899B2
Authority
AU
Australia
Prior art keywords
cells
isolated
antibody
cell
nkp30
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26677/01A
Other languages
English (en)
Other versions
AU2667701A (en
Inventor
Roberto Biassoni
Cristina Bottino
Alessandro Moretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Original Assignee
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2288307A external-priority patent/CA2288307C/en
Application filed by Innate Pharma SA, DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova filed Critical Innate Pharma SA
Publication of AU2667701A publication Critical patent/AU2667701A/en
Application granted granted Critical
Publication of AU783899B2 publication Critical patent/AU783899B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU26677/01A 1999-11-15 2000-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same Ceased AU783899B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44051499A 1999-11-15 1999-11-15
CA2288307 1999-11-15
US09/440514 1999-11-15
CA2288307A CA2288307C (en) 1999-11-15 1999-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
PCT/EP2000/011697 WO2001036630A2 (en) 1999-11-15 2000-11-15 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Publications (2)

Publication Number Publication Date
AU2667701A AU2667701A (en) 2001-05-30
AU783899B2 true AU783899B2 (en) 2005-12-22

Family

ID=25681295

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26677/01A Ceased AU783899B2 (en) 1999-11-15 2000-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Country Status (8)

Country Link
EP (1) EP1240326B1 (https=)
JP (1) JP4776845B2 (https=)
AT (1) ATE423848T1 (https=)
AU (1) AU783899B2 (https=)
DE (1) DE60041655D1 (https=)
DK (1) DK1240326T3 (https=)
ES (1) ES2321687T3 (https=)
WO (1) WO2001036630A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004056392A1 (en) * 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105848A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
EP1626059A1 (en) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
KR101662622B1 (ko) * 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
AU2016299166B2 (en) * 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
AU2018371114A1 (en) 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4448095A1 (en) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP7821427B2 (ja) * 2022-01-27 2026-02-27 学校法人 東洋大学 ナチュラルキラー細胞活性の測定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502089A (ja) * 1993-08-27 1997-03-04 ダナ−ファーバー キャンサー インスティチュート インコーポレイテッド ナチュラルキラー細胞特異性抗原およびこの抗原を識別する抗体
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
US7396681B1 (en) * 1998-03-27 2008-07-08 Gabriele Multhoff Application of Hsp70 proteins

Also Published As

Publication number Publication date
WO2001036630A9 (en) 2002-09-19
DK1240326T3 (da) 2009-06-02
JP2003523735A (ja) 2003-08-12
EP1240326A2 (en) 2002-09-18
ATE423848T1 (de) 2009-03-15
WO2001036630A2 (en) 2001-05-25
JP4776845B2 (ja) 2011-09-21
ES2321687T3 (es) 2009-06-10
DE60041655D1 (de) 2009-04-09
EP1240326B1 (en) 2009-02-25
AU2667701A (en) 2001-05-30
WO2001036630A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
AU783899B2 (en) Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
Pende et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells
Cantoni et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells
AU685745B2 (en) Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
WO1994027638A1 (en) Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells
WO1995029236A2 (en) Lymphocyte activation antigens and antibodies thereto
WO1995029236A9 (en) Lymphocyte activation antigens and antibodies thereto
CA2215905A1 (en) Monoclonal antibody reacting specifically with fas ligand and process for producing the same
US7138243B2 (en) NTB-A, a surface molecule involved in natural killer cells activity
AU676325B2 (en) Receptors of interleukin-12 and antibodies
AU2002325333A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
EP0830373A1 (en) Cd6 ligand
US20080248045A1 (en) Polypeptides having a triggering nk activity and biological applications
CA2288307C (en) Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 36, PAGE(S) 7808-7811 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 44276/00, 61751/00, 76984/00, 10413/01, 11280/01, 11545/01, 11657/01, 11680/01, 11717/01, 12665/01, 12881/01, 12892/01, 12898/01, 12911/01, 12916/01, 12958/01, 13149/01, 13715/01, 13788/01, 13928/01, 14014/01, 14030/01, 14043/01, 15162/01, 15204/01, 15284/01, 15430/01, 17116/01, 17119/01, 17128/01, 18572/01, 18837/01, 18840/01, 18842/01, 18852/01, 18854/01, 19018/01, 19973/01, 19988/01, 20137/01, 20141/01, 20143/01, 21499/01, 21567/01, 22362/01, 22363/01, 24211/01, 24817/01 AND 26677/01